Delphi panel for consensus on the optimal management of dabrafenib plus trametinib-related pyrexia in patients with melanoma.

Frazer, Ricky; Gupta, Avinash; Herbert, Christopher; Payne, Miranda; Diaz-Mendoza, Sergio; Vincent, Sally-Anne; Kovaleva, Elena

Frazer, Ricky; Gupta, Avinash; Herbert, Christopher; Payne, Miranda; Diaz-Mendoza, Sergio; Vincent, Sally-Anne; Kovaleva, Elena.

Afiliação

Frazer R; Consultant Medical Oncologist, Velindre University NHS Trust, Velindre Cancer Centre, Velindre Road, Cardiff, Wales CF14 2TL, UK.
Gupta A; The Christie NHS Foundation Trust, Manchester, England.
Herbert C; University Hospital Bristol, Bristol, England.
Payne M; Oxford University Hospitals NHS Trust, Oxford, England.
Diaz-Mendoza S; OPEN Health, Marlow, England.
Vincent SA; OPEN Health, Marlow, England.
Kovaleva E; Novartis Pharmaceuticals UK LTD, England.

Ther Adv Med Oncol ; 14: 17588359221127681, 2022.

Article em En | MEDLINE | ID: mdl-36339928

Palavras-chave

consensus; dabrafenib; melanoma; pyrexia; trametinib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Qualitative_research Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google